Pre-planned health economic analysis of SAKK 96/12: prevention of symptomatic skeletal events with denosumab administered every 4 weeks versus every 12 weeks – a non-inferiority phase III trial
Research Project | 01.05.2025 - 31.01.2028
|
01.05.2025
- 31.01.2028
Funding
Pre-planned health economic analysis of SAKK 96/12: prevention of symptomatic skeletal events with denosumab administered every 4 weeks versus every 12 weeks – a non-inferiority phase III trial
Krebsforschung Schweiz, 05.2025-01.2028 (33)
PI : Schwenkglenks, Matthias.CI : Templeton, Arnoud.
Members (2)
Matthias Schwenkglenks
Principal Investigator